Genmab A/S (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Analysts

Genmab A/S (NASDAQ:GMAB) has been given a consensus rating of “Moderate Buy” by the ten analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $45.20.

A number of research firms recently weighed in on GMAB. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Redburn Atlantic began coverage on Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Wednesday, January 8th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $20.80 on Tuesday. The firm has a market capitalization of $13.76 billion, a price-to-earnings ratio of 20.19, a PEG ratio of 0.59 and a beta of 0.97. The business has a 50 day simple moving average of $21.15 and a 200-day simple moving average of $24.06. Genmab A/S has a 1 year low of $19.85 and a 1 year high of $31.88.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The firm had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. During the same period in the previous year, the firm earned $0.47 earnings per share. As a group, analysts expect that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Several institutional investors and hedge funds have recently made changes to their positions in GMAB. Renaissance Technologies LLC raised its holdings in shares of Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after purchasing an additional 103,859 shares in the last quarter. Two Sigma Advisers LP raised its stake in Genmab A/S by 84.1% in the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after buying an additional 280,900 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in Genmab A/S by 109.7% during the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after buying an additional 145,689 shares during the period. FMR LLC boosted its position in Genmab A/S by 13.5% during the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock valued at $6,782,000 after acquiring an additional 33,076 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. increased its holdings in shares of Genmab A/S by 6.5% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company’s stock valued at $5,662,000 after acquiring an additional 14,165 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.